Skip to contentA
Agios Pharmaceuticals, Inc.
A
AGIOAgios Pharmaceuticals, Inc. Q1 2025 · 10-Q
Revenue$8.73M$8.73M+6.6% vs Q1 2024 Net Income-$89.29M-$89.29MN/M vs Q1 2024 EPS Diluted-$1.55-$1.55N/M vs Q1 2024 Operating Income-$106,629,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Agios Pharmaceuticals, Inc. · CIK 1439222 · Engraved from SEC EDGAR
Free Cash Flowderived-$112,255,000N/M Margins · derivedOperating margin-1222.0%−97.6 pt vs Q1 2024
Net margin-1023.3%−27.4 pt vs Q1 2024
ended Mar 31, 2025 · filed May 1, 2025 · 31 d after period end